Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor

Gut

Volumn 56, Issue 9, 2007, Pages 1210-1217

  Moss, Alan C ^b   Anton, Pauline ^b   Savidge, Tor ^c   Newman, Paul ^c   Cheifelz, Adam S ^b   Gay, Jerome ^d   Paraschos, Sophia ^b   Winter, Michael Weinstein ^b   Moyer, Mary P ^e   Karalis, Katia ^b   Kokkotou, Efi ^b   Pothoulakis, Charalabos ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROCORTIN; UROCORTIN II;

ARTICLE; BIOPSY TECHNIQUE; COLON CROHN DISEASE; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BACTERIAL TOXINS; CELL LINE; COLITIS; COLITIS, ULCERATIVE; COLON; CORTICOTROPIN-RELEASING HORMONE; CROHN DISEASE; ENTEROTOXINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; INTESTINES; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548130217     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.110668     Document Type: Article

References (49)

1. Grigoriadis DE, Lovenberg TW, Chalmers DT, et al. Characterization of corticotropin-releasing factor receptor subtypes. Ann N Y Acad Sci 1996;780:60-80.
2. Bamberger CM, Bamberger AM. The peripheral CRH/urocortin system. Ann N Y Acad Sci 2000;917:290-6.
3. Hsu SYHA. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001;7:605-11.
4. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001;98:2843-8.
5. la Fleur SE, Wick EC, Idumalla PS, et al. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc Natl Acad Sci USA 2005;102:7647-52.
6. Chen ABA, Vaughan J, Brar B, et al. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology 2004;145:2445-57.
7. Martinez VWL, Rivier JE, Vale W, et al. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002;301:611-7.
8. Soshinami H, Kageyama K, Suda T, et al. Urocortin 2 suppresses host resistance to Listeria monocytogenes infection via up-regulation of interleukin-10. Endocrinology 2005;146:5003-11.
9. Tsatsanis C, Androulidaki A, Dermitzaki E, et al. Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005;579:4259-64.
10. Catalano RD, Kyriakou T, Chen J, et al. Regulation of corticotropin-releasing hormone type 2 receptors by multiple promoters and alternative splicing: identification of multiple splice variants. Mol Endocrinol 2003;17:395-410.
11. Kostich WA, Chen A, Sperle K, et al. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 1998;12:1077-85.
12. Valdenaire O, Giller T, Breu V, et al. A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochim Biophys Acta 1997;1352:129-32.
13. Kokkotou E, Torres A. Moss AC, et al. Corticotropin- releasing hormone receptor 2 deficient mice have reduced intestinal inflammatory responses. J Immnol 2006;177:3355-61.
14. Kageyama K, Furukawa K, Miki I, et al. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol 2003;42:561-5.
15. Wlk M, Wang CC, Venihaki M, et al. Corticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology 2002;123:505-15.
16. Savidge TC, Pan WH, Newman P, et al. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003;125:413-20.
17. Rivier J, Gulyas J, Kirby D, et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 2002;45:4737-47.
18. Rivier CL, Grigoriadis DE, Rivier JE. Role of corticotropin- releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. Endocrinology 2003;144:2396-403.
19. Zhao D, Keates AC, Kuhnt-Moore S, et al. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001;276:44464-71.
20. Cao J, Cetrulo CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol 2006;69:998-1006.
21. Darmoul D, Gratio V, Devaud H, et al. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003;162:1503-13.
22. Sawhney RS, Sharma B, Humphrey LE, et al. Integrin alpha2 and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha-driven colon cancer cells. J Biol Chem 2003;278:19861-9.
23. Jobin C, Hellerbrand C, Licato LL, et al. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998;42:779-87.
24. Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
25. Scherer DC, Brockman JA, Chen Z, et al. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA 1995;92:11259-63.
26. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998;43:29-32.
27. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
28. Castagliuolo I, Riegler M, Pasha A, et al. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J Clin Invest 1998;101:1547-50.
29. Simoncini T, Apa R, Reis FM, et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 1999;84:2802-6.
30. He D, Sougioultzis S, Hagen S, et al. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 2002;122:1048-57.
31. Jefferson KK, Smith MF Jr, Bobak DA. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 1999;163:5183-91.
32. Warny M, Keates AC, Keates S, et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 2000;105:1147-56.
33. Moyer MP, Manzano LA, Merriman RL, et al. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 1996;32:315-7.
34. Karagiannides I, Kokkotou E, Tansky M, et al. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci USA 2006;103:5207-12.
35. Rhee SH, Keates AC, Moyer MP, et al. MEK is a key modulator for TLR5-induced interleukin-8 and MIP3alpha gene expression in non-transformed human colonic epithelial cells. J Biol Chem 2004;279:25179-88.
36. Perrin M, Donaldson C, Chen R, et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 1995;92:2969-73.
37. Chatzaki E, Crowe PD, Wang L, et al. CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. J Neurochem 2004;90:309-16.
38. Chen A, Perrin M, Brar B, et al. Mouse corticotropin- releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol 2005;19:441-58.
39. Castagliuolo I, Karalis K, Valenick L, et al. Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G539-45.
40. Papadopoulou NG, Oleson L, Kempuraj D, et al. Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells. J Mol Endocrinol 2005;35:R1-8.
41. Kageyama K, Suda T. Regulation of corticotropin-releasing factor receptor type 2beta messenger ribonucleic acid by interleukin-1beta in rat vascular smooth muscle cells. Neuroimmunomodulation 2001;9:326-32.
42. Saruta M, Takahashi K, Suzuki T, et al. Urocortin 1 in colonic mucosa in patients with ulcerative colitis. J Clin Endocrinol Metab 2004;89:5352-61.
43. Kawahito Y, Sano H, Mukai S, et al. Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis. Gut 1995;37:544-51.
44. Brar BK, Chen A, Perrin MH, et al. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 2004;145:1718-29.
45. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 2006;55:824-32.
46. Zhao J, Karalis KP. Regulation of nuclear factor-kappaB by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol 2002;16:2561-70.
47. Zbytek B, Pfeffer LM, Slominski AT. Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J Endocrinol 2004;181:R1-7.
48. Tache Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 2004;16(Suppl 1):137-42.
49. Anton PM, Gay J, Mykoniatis A, et al. Corticotropin- releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci USA 2004;101:8503-8.